Free Trial

Tonix Pharmaceuticals (TNXP) Competitors

Tonix Pharmaceuticals logo
$28.61 -2.60 (-8.33%)
Closing price 04:00 PM Eastern
Extended Trading
$28.82 +0.22 (+0.75%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TNXP vs. MAZE, PHAR, SPRY, ATAI, CRON, UPB, CRMD, SYRE, QURE, and ABUS

Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Maze Therapeutics (MAZE), Pharming Group (PHAR), ARS Pharmaceuticals (SPRY), atai Life Sciences (ATAI), Cronos Group (CRON), Upstream Bio (UPB), CorMedix (CRMD), Spyre Therapeutics (SYRE), uniQure (QURE), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

Tonix Pharmaceuticals vs. Its Competitors

Tonix Pharmaceuticals (NASDAQ:TNXP) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Tonix Pharmaceuticals presently has a consensus price target of $70.00, indicating a potential upside of 144.67%. Maze Therapeutics has a consensus price target of $30.17, indicating a potential upside of 29.47%. Given Tonix Pharmaceuticals' higher probable upside, equities research analysts clearly believe Tonix Pharmaceuticals is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Maze Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25

Maze Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -828.22%. Maze Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals-828.22% -57.93% -51.04%
Maze Therapeutics N/A N/A N/A

Maze Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tonix Pharmaceuticals$9.83M25.51-$130.04M-$39.47-0.72
Maze Therapeutics$167.50M6.10$52.23MN/AN/A

In the previous week, Maze Therapeutics had 19 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 22 mentions for Maze Therapeutics and 3 mentions for Tonix Pharmaceuticals. Maze Therapeutics' average media sentiment score of 0.97 beat Tonix Pharmaceuticals' score of 0.63 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tonix Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maze Therapeutics
8 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Maze Therapeutics beats Tonix Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNXP vs. The Competition

MetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$250.80M$2.84B$5.78B$10.15B
Dividend YieldN/A56.65%5.69%4.61%
P/E Ratio-0.7223.5374.5925.92
Price / Sales25.51534.82453.9085.92
Price / CashN/A169.2537.0859.91
Price / Book0.905.3712.156.29
Net Income-$130.04M$32.95M$3.28B$270.85M
7 Day Performance7.80%1.31%0.98%3.36%
1 Month Performance-52.13%8.31%7.20%6.41%
1 Year Performance79.15%0.29%63.06%28.26%

Tonix Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNXP
Tonix Pharmaceuticals
3.2764 of 5 stars
$28.61
-8.3%
$70.00
+144.7%
+107.9%$250.80M$9.83M-0.7250Gap Down
MAZE
Maze Therapeutics
N/A$23.79
-4.1%
$30.17
+26.8%
N/A$1.04B$167.50M0.00121Trending News
Analyst Forecast
PHAR
Pharming Group
2.075 of 5 stars
$14.95
+1.0%
$30.00
+100.7%
+102.7%$1.02B$297.20M-115.00280News Coverage
Positive News
Short Interest ↑
Gap Up
SPRY
ARS Pharmaceuticals
2.6595 of 5 stars
$10.11
-0.4%
$32.50
+221.4%
-15.4%$996.90M$89.15M-20.5990Positive News
ATAI
atai Life Sciences
2.8835 of 5 stars
$4.66
+1.2%
$11.25
+141.7%
+268.0%$991.31M$2.31M-6.7080
CRON
Cronos Group
2.5042 of 5 stars
$2.57
-0.6%
N/A+18.3%$982.11M$117.61M51.30450
UPB
Upstream Bio
1.9734 of 5 stars
$18.09
+0.9%
$56.50
+212.4%
N/A$974.96M$2.37M0.0038Positive News
CRMD
CorMedix
3.9043 of 5 stars
$13.04
-0.4%
$18.00
+38.0%
+89.4%$973.44M$43.47M17.3930Trending News
Analyst Forecast
Insider Trade
Short Interest ↑
SYRE
Spyre Therapeutics
2.3411 of 5 stars
$15.88
-2.0%
$53.40
+236.3%
-44.1%$959.45M$890K-4.6773Positive News
QURE
uniQure
3.1566 of 5 stars
$17.04
+0.6%
$37.45
+119.8%
+209.7%$934.93M$14.34M-4.35500
ABUS
Arbutus Biopharma
2.0311 of 5 stars
$4.68
-4.6%
$5.00
+7.0%
+7.5%$901.95M$6.17M-16.2290News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:TNXP) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners